Mathias Schmidt, Ph.D., CEO, Armagen
Mathias obtained his master in Biotechnology from the University of Stuttgart. He gained his PhD in oncology from the Tumor Biology Center of the University of Freiburg, where he developed a Her-2 specific immunotoxin that was subsequently brought to the clinic. After working for several years at various cancer hospitals in Germany and the U.S. he joined the pharmaceutical industry in 1999. He developed a great passion for drug discovery and development, especially for protein therapeutics. In 2011 he was awarded the venia legendi in pharmacology from the University of Konstanz.